Inflammation is the body’s innate response to injury or insult, including infection, trauma, surgery, burns, and cancer. Certain proteins are released into the bloodstream during inflammation; if their concentrations increase or decrease by at least 25%, they can be used as systemic inflammatory markers. Although there are many inflammatory markers, also known as acute phase reactants, those most commonly measured in clinical practice (and discussed in this topic) are C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT). PCT is a newer marker of inflammation that may, in certain cases, identify or exclude bacterial infections and guide antibacterial treatments. Because these markers are nonspecific, the tests alone are not diagnostic for a particular condition, but they may help to identify a generalized inflammatory state along with other tests and aid in the differential diagnosis. In some diseases, serial measurements of CRP also may be of prognostic value.
Quick Answers for Clinicians
Besides C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT), some other markers of inflammation include serum amyloid A, cytokines, alpha-1-acid glycoprotein, plasma viscosity, ceruloplasmin, hepcidin, and haptoglobin. However, high cost, limited availability, and lack of standardization may limit practical clinical use of markers other than CRP, ESR, and PCT in the evaluation of inflammation. Yet some acute phase proteins, for example, alpha-1 antitrypsin, fibrinogen and coagulation factors, and complement factors, serve a role in specific diagnoses. Information on the hepatic proteins albumin, prealbumin (transthyretin), retinol-binding protein (RBP), and transferrin can be found in the Hepatic Proteins topic.
Many tests, including those used for measuring erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and procalcitonin (PCT), have not been fully standardized or harmonized ; ie, the assay and the performance thereof may vary between laboratories, which may lead to significant variation in results. Thus, results require careful interpretation, as variation in results may lead to inappropriate clinical decision making and potentially adverse impacts on patient care. Repeat testing should be performed using the same assay and laboratory to maximize consistency. Furthermore, ESR testing requires age- and sex-specific reference limits.
Guided antibiotic stewardship (ABS) is the practice of using biomarkers to guide decisions about initiation and discontinuation of antibiotic treatment to avoid misuse and overuse in patients. Overuse can lead to bacterial resistance to antimicrobial drugs. Both C-reactive protein (CRP) and procalcitonin (PCT) levels have been shown to be useful tools for the optimization of antibiotic therapy ; because these tests can reveal disease severity and resolution of illness, results can indicate whether antibiotics should be initiated, withheld, or discontinued.
Indications for Testing
Inflammatory processes are a component of a wide range of diseases. CRP, ESR, and PCT are general, nonspecific tools that may be useful in specific scenarios. Testing of inflammatory markers can be used in conjunction with a patient’s overall clinical picture to
- Aid in the diagnosis of certain suspected inflammatory disorders (eg, ESR is used for giant cell arteritis and CRP for neonatal sepsis)
- Distinguish between inflammatory and noninflammatory diseases (eg, osteoarthritis versus rheumatoid arthritis or inflammatory bowel disease versus irritable bowel syndrome)
- Manage certain antibiotic therapies (eg, PCT can be used to support shortening the duration of antimicrobial therapy in patients with lower respiratory tract infections)
- Predict recovery (eg, PCT can be used to predict 28-day cumulative mortality risk for patients diagnosed with sepsis)
CRP concentrations are a reliable, early indicator of active systemic inflammation, as they can help differentiate inflammatory from noninflammatory conditions and also reflect the severity of the inflammatory insult. CRP is recommended over ESR to detect acute phase inflammation in patients with undiagnosed conditions because it is more sensitive and specific than ESR. CRP has a narrow range of normal values, usually <3-10 mg/L in the blood, but during infection or inflammatory conditions, levels can rise several hundred-fold. CRP is a useful measure also because concentrations change rapidly within the first 6-8 hours after injury, peak after 48 hours, and return to normal levels again once the issue has resolved. Additionally, some studies indicate that ratios of serial CRP measurements to the CRP level at admission may be associated with outcomes in critically ill patients. In critically ill patients and those in the intensive care unit (ICU), PCT has greater accuracy and may be preferable to CRP, as the specificity and sensitivity of CRP are lower and peak levels may not correspond to the severity of inflammation.
High-sensitivity CRP (hsCRP) is not used for the same purposes as CRP and should not be used in the assessment of general inflammatory processes. For recommended uses for this test, see the Atherosclerotic Cardiovascular Disease Risk Markers topic.
Erythrocyte Sedimentation Rate
ESR is an indirect measurement of plasma protein concentrations and is influenced by a number of disease states. Because ESR depends on several proteins with varying half-lives, the rate rises and falls more slowly than do CRP concentrations. Furthermore, normal ESR values are specific to age and sex, as the rate increases steadily with age and is higher in women than in men. Although CRP measurements have a clear advantage over ESR, ESR remains a useful test in the diagnosis of select conditions, particularly general bone lesions and osteomyelitis.
The release of PCT into the circulation is most often induced by bacterial infection, but increases can also result from other causes, including severe viral infection, pancreatitis, tissue trauma, and certain autoimmune disorders. Furthermore, PCT elevations are not usually associated with bacterial colonization, localized bacterial infection, or allergic responses. In the diagnosis of sepsis, increased PCT levels have a high positive predictive value, and normal levels have a high negative predictive value.
PCT measurements can also be used to help personalize treatment, manage antibiotic prescriptions, and reduce antibiotic exposure, which has prompted the U.S. Food and Drug Administration (FDA) to approve the use of PCT testing to guide antibiotic use in patients in the United States with acute respiratory illnesses.
Because CRP levels fall quickly once the cause of inflammation has resolved, CRP is a useful marker for monitoring disease activity and response to or need for treatment. Studies have shown that CRP levels decrease faster during the first 48 hours with adequate treatment and that increases in CRP concentrations over 48 hours predict inadequate therapy. Guidelines recommend waiting at least 24 hours before repeating CRP measurements, except in neonates, in whom testing is recommended after 18-24 hours. PCT measurements also may provide similarly useful information for treatment decisions and disease monitoring.
ARUP Lab Tests
Detect acute phase inflammation
Do not order for cardiovascular disease risk assessment
Detect inflammation associated with infections, cancers, and autoimmune diseases
Assess risk of progression to severe sepsis and septic shock in critically ill patients upon admission to ICU
Clin Chem Lab Med2019PubMed
Biomed Res Int20132013124021PubMed
ABC - C-reactive protein and erythrocyte sedimentation rate: Continuing role for erythrocyte sedimentation rate.Advances in Biological ChemistryApr 2019Online
Jul 2015IssuedJul 2015Mar 2019Online
Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients--calculated sample size: 1816 patients.BMC Infect Dis201313178PubMed
Ann Transl Med2017510208PubMed
N Engl J Med19993406448-54PubMed
American Society for Clinical PathologyApr 2019Online
Arch Dis Child Educ Pract Ed201499398-100PubMed
Meisner M. Procalcitonin: Biochemistry and Clinical Diagnosis, Bremen: UNI-MED-Verlag, 2010.
Br J Gen Pract